ADC Therapeutics SA
ADCT- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001771910
No open-market purchases or sales by ADC Therapeutics SA insiders were filed in the last 90 days; 113 institutions reported holding it in 13F filings for Q2 2026, worth $86.3M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in ADC Therapeutics SA as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 115
- +9 vs. Q3 2025
- Shares held
- 82.9M
- +15.0M (+22.2%) vs. Q3 2025
- Total value
- $292.8M
- +$21.5M (+7.9%) vs. Q3 2025
- New holders
- 21
- 48 more added
- Sold out
- 12
- 27 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ADCT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 113 | $86.3M |
| Q1 2026 | 118 | $312.9M |
| Q4 2025 | 115 | $292.8M |
| Q3 2025 | 106 | $271.3M |
| Q2 2025 | 86 | $182.1M |
| Q1 2025 | 82 | $77.3M |
| Q4 2024 | 83 | $112.4M |
| Q3 2024 | 77 | $172.9M |
| Q2 2024 | 74 | $163.7M |
| Q1 2024 | 37 | $155.8M |
| Q4 2023 | 38 | $56.4M |
| Q3 2023 | 41 | $35.4M |
| Q2 2023 | 56 | $97.5M |
| Q1 2023 | 59 | $90.9M |
| Q4 2022 | 60 | $149.1M |
| Q3 2022 | 66 | $176.5M |
| Q2 2022 | 58 | $274.1M |
| Q1 2022 | 49 | $501.3M |
| Q4 2021 | 55 | $682.8M |
| Q3 2021 | 53 | $890.6M |
| Q2 2021 | 56 | $816.3M |
| Q1 2021 | 59 | $801.3M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding ADC Therapeutics SA; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Platinum Investment Management Ltd | 990,778 | $3.50M | 0.81% | −165,943−14.3% | Reduced |
| Geode Capital Management, LLC | 996,523 | $3.52M | 0.00% | +133,589+15.5% | Added |
| Vanguard Group Inc | 1,129,587 | $3.99M | 0.00% | +535,633+90.2% | Added |
| Bank of America Corp | 1,298,584 | $4.58M | 0.00% | −62,706−4.6% | Reduced |
| State Street Corp | 1,407,325 | $4.97M | 0.00% | +111,384+8.6% | Added |
| Goldman Sachs Group Inc | 1,640,872 | $5.79M | 0.00% | +46,438+2.9% | Added |
| Eventide Asset Management, LLC | 3,364,067 | $11.9M | 0.19% | +3,364,067 | New |
| Morgan Stanley | 3,769,743 | $13.3M | 0.00% | +100,676+2.7% | Added |
| Point72 Asset Management, L.P. | 5,014,617 | $17.7M | 0.03% | −3,121,034−38.4% | Reduced |
| BlackRock, Inc. | 5,427,309 | $19.2M | 0.00% | +915,610+20.3% | Added |
| Nantahala Capital Management, LLC | 5,475,433 | $19.3M | 1.15% | +3,209,144+141.6% | Added |
| OrbiMed Advisors LLC | 5,822,854 | $20.6M | 0.42% | −84,497−1.4% | Reduced |
| Prosight Management, LP | 8,477,338 | $29.9M | 6.18% | +1,005,035+13.5% | Added |
| TCG Crossover Management, LLC | 11,390,175 | $40.2M | 1.33% | +10,000,000+719.3% | Added |
| Redmile Group, LLC | 15,666,731 | $55.3M | 4.07% | 00.0% | Unchanged |
| Lynx1 Capital Management LP | 0 | $0 | 0.00% | −1,325,848−100.0% | Sold out |
| Opaleye Management Inc. | 0 | $0 | 0.00% | −682,529−100.0% | Sold out |
| Heights Capital Management, Inc | 0 | $0 | 0.00% | −326,766−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −177,032−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −159,993−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −27,531−100.0% | Sold out |
| R Squared Ltd | 0 | $0 | 0.00% | −14,714−100.0% | Sold out |
| Diversified Trust Co | 0 | $0 | 0.00% | −14,115−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −13,131−100.0% | Sold out |
| UMA Financial Services, Inc. | 0 | $0 | 0.00% | −228−100.0% | Sold out |
| Clearstead Advisors, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| TSFG, LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |